Summary
The effects of oral doses of the dopamine antagonist antiemetics metoclopramide and domperidone on baseline and dopamine stimulated renal function and systemic haemodynamics were assessed in a placebo controlled crossover study in 9 healthy volunteers.
Metoclopramide did not change baseline ERPF, GFR or FF over 2 h post dosing but it significantly reduced baseline UNaV, UKV, urine flow, urinary dopamine excretion, supine and erect diastolic blood pressure and supine systolic blood pressure. Domperidone and placebo did not cause these effects.
Metoclopramide caused a marked rise and domperidone a small fall in plasma aldosterone concentration (PAC) but placebo was without effect. Neither antiemetic altered plasma renin activity (PRA) but a small fall occurred with placebo.
Two hours after pretreatment with placebo dopamine (2 μg/kg/min) increased effective renal plasma flow (ERPF), glomerular filtration rate (GFR), sodium excretion rate (UNaV), urine flow rate, urinary dopamine excretion rate, supine systolic blood pressure and supine and erect pulse rate and decreased the potassium excretion rate (UKV), filtration fraction (FF) and supine diastolic blood pressure.
Metoclopramide pretreatment, did not attenuate the dopamine induced rise in ERPF, GFR, urine flow, urinary dopamine excretion or supine systolic blood pressure but it did attenuate the rise in pulse rate, the fall in diastolic pressure, and the antikaliuretic effect of dopamine leading to a net kaliuresis when compared to placebo. Domperidone was similar to placebo.
Neither metoclopramide nor domperidone given orally caused clinically important antagonism of the renal haemodynamic effects of dopamine. However the effects of metoclopramide on blood pressure and electrolyte excretion may have clinical importance.
Metoclopramide has significant pharmacodynamic effects which are probably not due to DA2 antagonism but may be mediated by DA1 antagonism or be non-specific.
Similar content being viewed by others
Abbreviations
- DA:
-
dopamine
- ERPF:
-
effective renal plasma flow
- FF:
-
filtration fraction
- GFR:
-
glomerular filtration rate
- PAC:
-
plasma aldosterone concentration
- PRA:
-
plasma renin activity
- UV:
-
urine flow rate
- UNaV:
-
urinary sodium excretion rate (natriuresis)
- UKV:
-
urinary potassium excretion rate (kaliuresis)
- HPLC:
-
high performance liquid chromatography.
References
McDonald RH, Goldberg LI, McNay JL, Tuttle EP (1964) Effects of dopamine in man: augmentation of sodium excretion, glomerular filtration rate and renal plasma flow. J Clin Invest 43: 1116–1124
Smit AJ, Meijer S, Wessling H, Reitsma WD, Donker AJM (1987) The dose-response effect of intravenous dopamine on renal function in normal man and in patients with renal disease. Kidney Int 31: 1044–1045
Felder RA, Felder CC, Eisner GM, Jose P (1989) Renal dopamine receptors. In: Peripheral actions of dopamine. Bell C, McGrath B (eds), MacMillan, New York, pp 124–140
Smit AJ, Meijer S, Wesseling H, Donker AMJ, Reitsma WD (1988) Effect of metoclopramide on dopamine-induced changes in renal function in healthy controls and in patients with renal disease. Clin Sci 75: 421–428
Cavero I, Massingham R, Lefevre-Borg T (1982) Peripheral dopamine receptors, potential sites for a new class of antihypertensive agents. Part 1: subclassification and functional description. Life Sci 31: 939–948
Kohli JD, Glock D, Goldberg LI (1982) Differential antagonism of postsynaptic (DA1) and presynaptic (DA2) peripheral dopamine receptors by substituted benzamides. In: Rotrosen J, Stanley M (eds) The benzamides: pharmacology, neurobiology and clinical aspects. Raven Press, New York, pp 97–108
Langer SZ (1981) Presynaptic regulation of the release of catecholamines. Pharmacol Rev 32: 337–367
Jose PA, Felder RA, Robillard JE, Felder CC, Eisner GM (1986) Dopamine-2 receptors in the canine kidney. Kidney Int 29: 385
Felder RA, Belcher M, Eisner GM, Jose PA (1984) Cortical tubular and glomerular dopamine receptors in the rat kidney. Am J Physiol 246: F557-F568
Kohli JD, Glock D, Goldberg LI (1983) Selective DA2 versus DA1 antagonist activity of domperidone in the periphery. Eur J Pharmacol 89: 137–141
Dawborn JK (1965) Application of Heyrousky's inulin method to automatic analysis. Clin Chim Acta 12: 63–66
Harvey RB, Brothers AJ (1962) Renal extraction of para-aminohippurate and creatinine measured by continuous in vivo sampling of arterial and renal vein blood. Ann New York Acad Sci 120: 46–54
Haber E, Koerner T, Page LB, Kliman B, Purnode A (1969) Application of a radioimmunoassay for angiotensin I to the physiologic measurements of plasma renin activity in normal human subjects. J Clin Endocrinol 29: 1349–1355
Heykants J, Hendriks R, Meuldermans W, Michiels M, Scheygrond H, Reyntjens H (1981) On the pharmacokinetics of domperidone in animals and man IV: The pharmacokinetics of intravenous domperidone and its bioavailability in man following intramuscular, oral and rectal administration. Eur J Drug Metab Pharmacokin 6: 61–70
Bateman DN, Gokal R, Dodd TRP, Blain PG (1981) The pharmacokinetics of single doses of metoclopramide in renal failure. Eur J Clin Pharmacol 19: 437–441
Anton AH, Sayre DF (1964) The distribution of dopamine and dopa in various animals and a method of their determination in diverse biological material. J Pharmacol Exper Ther 145: 326–336
MacDonald TM, Jeffrey RF, Freestone S, Lee MR (1988) (+)-sulpiride attenuates the renal effects of gamma-L-glutamyl-L-dopa in man. Br J Clin Pharmacol 25: 203–212
Stote RM, Dubb JW, Familiar RG, Erb BB, Alexander F (1983) A new oral vasodilator, fenoldopam. Clin Pharmacol Ther 34: 309–315
Hahn RA, Wardell JR (1980) Antagonism of the renal vasodilation activity of dopamine by metoclopramide. Naunyn Schmiedebergs Arch Pharmacol 314: 177–182
Albibi R, McCallu RW (1983) Metoclopramide: Pharmacology and clinical applications. Ann Int Med 98: 86–95
Braley LM, Menachery AI, Williams GH (1983) Specificity of metoclopramide in assessing the role of dopamine in regulating aldosterone secretion. Endocrinology 112: 1352–1357
Fang VS, Shian LR (1981) A seratonergic mechanism of the prolactin-stimulating action of metoclopramide. Endocrinology 108: 1622–1627
Spedding M (1980) Effects of metoclopramide and isoprenaline in the rat vas deferens: interactions with α-adrenoceptors. Br J Pharmacol 71: 113–120
Bevilacqua M, Norbiato G, Raggi U, Micossi P, Baggio E, Prandeli M (1980) Dopaminergic control of serum potassium. Metabolism 29: 306–310
Sheridan C, Chardra P, Jacinto M, Greenwald ES (1982) Transient hypertension after high doses of metoclopramide. N Engl J Med 307: 1346
Kuchel O, Buu NT, Hamet P, Larochelle P (1985) Effect of metoclopramide on plasma catecholamine release in essential hypertension. Clin Pharmacol Ther 37: 372–375
Mannelli M, Feo ML, Maggi M, Salvetti A, Giusti G, Serio M (1985) Does endogenous dopamine modulate human sympathetic activity through DA2 receptors? Eur J Clin Pharmacol 29: 159–164
Ennis C, Cox B (1980) The dopamine receptor antagonist domperidone is also a competitive antagonist at alpha1-adrenoceptors. J Pharm Pharmacol 32: 434
Osborne RJ, Slevin ML, Hunter RW, Hamer J (1985) Cardiotoxicity of intravenous domperidone. Lancet II: 385
Heykants J, Hendriks R, Meuldermans W, Michiels M, Scheygrond H, Reyntjens H (1981) On the pharmacokinetics of domperidone in animals and man IV: The pharmacokinetics of intravenous domperidone and its bioavailability in man following intramuscular, oral and rectal administration. Eur J Drug Metab Pharmacokin 6: 61–70
Ross-Lee LM, Eadie MJ, Hooper MJ, Bochner F (1981) Single-dose pharmacokinetics of metoclopramide. Eur J Clin Pharmacol 20: 465–471
Graffner C, Lagerstrom P, Lundborg P, Ronn O (1979) Pharmacokinetics of metoclopramide intravenously and orally determined by liquid chromatography. Br J Clin Pharmacol 8: 469–474
Bateman DN, Kahn C, Davies DS (1980) The pharmacokinetics of metoclopramide in man with observations in the dog. Br J Clin Pharmacol 9: 371–377
Carey RM, Thorner MO, Ortt EM (1980) Dopaminergic inhibition of metoclopramide-induced aldosterone secretion in man. J Clin Invest 66: 10–18
Norbiato GM, Bevilacqua M, Raggi D, Micossi P, Moroni C (1977) Metoclopramide increases aldosterone secretion in man. J Clin Endocrinol Metab 45: 1313–1316
Dupont AG, Vanderniepen P, Smitz JJ, Six RO (1985) Stimulation of aldosterone secretion by metoclopramide is not affected by chronic converting enzyme inhibition. Eur J Clin Pharmacol 29: 207–210
Harrington RA, Hamilton CW, Brogden RN, Linkewich JA, Romankiewicz JA, Heel RC (1983) Metoclopramide: an updated review of its pharmacological properties and clinical use. Drugs 25: 451–494
North RH, McCallum RW, Contino C, Havelick J (1980) Tonic dopaminergic suppression of plasma aldosterone. J Clin Endocrinol Metab 51: 64–69
Sowers JR, Brickman AS, Sowers DK, Berg G (1981) Dopaminergic modulation of aldosterone secretion in man is unaffected by glucocorticoids and angiotensin blockade. J Clin Endocrinol Metab 52: 1078–1084
Ganguly A (1984) Dopaminergic regulation of aldosterone secretion: how credible? Clin Sci 66: 631–637
Fraser R (1987) Dopamine regulation of aldosterone secretion: an open question? J Endocrinol 112: 179–181
Breckenridge A, Orme M, Dollery CT (1971) The effects of dopamine on renal blood flow in man. Eur J Clin Pharmacol 3: 131–136
Hollenberg NK, Adams DF, Mendell P, Abrams HL, Merril JP (1973) Renal vascular responses to dopamine: haemodynamic and angiographic observations in normal man. Clin Sci Mol Med 45: 733–742
Levinson PD, Goldstein DS, Munson PJ, Gill JR, Keiser HR (1985) Endocrine, renal and haemodynamic responses to graded dopamine infusions in normal men. J Clin Endocrinol Metab 60: 821–826
Orme ML, Breckenridge A, Dollery CT (1973) The effects of long term administration of dopamine on renal function in hypertensive patients. Eur J Clin Pharmacol 6: 150–155
Hughes A, Thom S, Martin G, Redman D, Hasan S, Sever P (1986) The action of a dopamine (DA1) receptor agonist, fenoldopam in human vasculature in vivo and in vitro. Br J Clin Pharmacol 22: 535–540
Jeffrey RF, MacDonald TM, Critchley JAJH, Lee MR (1986) Urinary dopamine-sodium relationships under basal and frusemide-stimulated states. Scot Med J 31: 213 (Abstract)
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
MacDonald, T.M. Metoclopramide, domperidone and dopamine in man: actions and interactions. Eur J Clin Pharmacol 40, 225–230 (1991). https://doi.org/10.1007/BF00315200
Received:
Accepted:
Issue Date:
DOI: https://doi.org/10.1007/BF00315200